Annemarie B. van der Aart‐van der Beek

Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial

Charlotte C. van Ruiten, Annemarie B. van der Aart‐van der Beek, Richard G. IJzerman et al. · Diabetes Obesity and Metabolism · 2021 · 52 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Simple, fast and robust LC-MS/MS method for the simultaneous quantification of canagliflozin, dapagliflozin and empagliflozin in human plasma and urine

Annemarie B. van der Aart‐van der Beek, A. Mireille A. Wessels, Hiddo J.L. Heerspink et al. · Journal of Chromatography B · 2020 · 43 citations · Full text

Pharmacy, Pharmaceutical Analysis, Pharmacology +17

Effect of once‐weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A <i>post hoc</i> analysis of the <scp>EXSCEL</scp> trial

Annemarie B. van der Aart‐van der Beek, Lindsay E. Clegg, Robert C. Penland et al. · Diabetes Obesity and Metabolism · 2020 · 36 citations · Full text

Pharmacy, Endocrinology, Pharmacotherapy +17

Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study

Annemarie B. van der Aart‐van der Beek, Ellen M. Apperloo, Niels Jongs et al. · Diabetes Obesity and Metabolism · 2023 · 29 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials

Annemarie B. van der Aart‐van der Beek, Daniël H. van Raalte, Cristian Guja et al. · Diabetes Obesity and Metabolism · 2020 · 26 citations · Full text

Pharmacy, Endocrinology, Pharmacotherapy +17